BioMap inks strategic AI collaboration with Sanofi

11 October 2023
sanofi_paris_large

BioMap today announced a ground-breaking strategic collaboration with French pharma major Sanofi (Euronext: SAN) to co-develop cutting-edge artificial intelligence (AI) modules for biologic therapies leveraging BioMap’s AI platform.

The Menlo Park, USA, and Beijing-based company was set up by the co-founder and former chief executive of Chinese search engine group Baidu, Robin Li, as well as Baidu Ventures’ former chief executive Wei Liu.

Sanofi also has a relationship with Baidu (Nasdaq: BIDU), as it has been working with the company since 2021 on the application of computational biology and AI algorithms to the design of mRNA-based therapeutics and vaccines with improved stability and activity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology